- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | BIOSERGEN AB: Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3 | 2 | Cision News | ||
| 03.12. | Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3 | 1 | Cision News | ||
| 03.12. | Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3 | 1 | Cision News | ||
| 26.11. | BIOSERGEN AB: Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections | 1 | Cision News | ||
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 26.11. | The last day of trading with the warrants of series TO3 in Biosergen AB is today, November 26, 2024 | 1 | Cision News | ||
| 21.11. | BIOSERGEN AB: Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005 | 1 | Cision News | ||
| 18.11. | BIOSERGEN AB: Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million | 1 | Cision News | ||
| 18.11. | The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49 | 1 | Cision News | ||
| 13.11. | BIOSERGEN AB: Biosergen discusses positive results in patients with deadly fungal infections | 2 | Cision News | ||
| 08.11. | Biosergen AB: Biosergen publishes interim report for third quarter 2024 | 59 | GlobeNewswire (Europe) | Friday November 8, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the... ► Artikel lesen | |
| 07.11. | BIOSERGEN AB: Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial | 1 | Cision News | ||
| 06.11. | BIOSERGEN AB: Biosergen's CEO: "I'm optimistic that we may cure patients" | 2 | Cision News | ||
| 31.10. | BIOSERGEN AB: Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections | 1 | Cision News | ||
| 18.10. | BIOSERGEN AB: Biosergen advances BSG005 antifungal drug candidate trial | 1 | Cision News | ||
| 07.10. | Biosergen AB: Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial | 84 | GlobeNewswire (Europe) | October 7, 2024 - Biosergen AB ("Biosergen"), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first... ► Artikel lesen | |
| 06.09. | BIOSERGEN AB: Biosergen's CEO: "The first patient regained his health" | 1 | Cision News | ||
| 05.09. | Biosergen - Optimism after treatment success - Mangold Insight Analysis | 1 | Cision News | ||
| 30.08. | Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005 | 2 | GlobeNewswire (USA) | ||
| 30.08. | BIOSERGEN AB: Biosergen publishes interim report for second quarter 2024 | 1 | Cision News | ||
| 12.07. | BIOSERGEN AB: First Patient in Biosergen Clinical Trial Treating with BSG005 for Life Threatening Fungal Infection | 1 | Cision News |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| JANUX THERAPEUTICS | 62,36 | 0,00 % | Janux Therapeutics notches fresh record after $350 million equity raise | ||
| BEAM THERAPEUTICS | 30,200 | 0,00 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,460 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability | REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 50,65 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen | |
| CG ONCOLOGY | 33,700 | 0,00 % | CG Oncology Inc.: CG Oncology Announces Proposed Public Offering | ||
| QIAGEN | 43,985 | +0,64 % | Biotech Report: Evotec und Qiagen behauptet; US-Sektor legt zu | (shareribs.com) Frankfurt / New York 04.12.2024 - Biotech-Aktien zeigten sich im deutschen Handel überwiegend leichter. Unter anderem gaben 4SC und Vita34 nach. Für Evotec ging es leicht nach oben.... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 8,930 | 0,00 % | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 12,950 | 0,00 % | ARS Pharmaceuticals, Inc. - 10-Q/A, Quarterly Report | ||
| ARCELLX | 82,25 | 0,00 % | Safety Stands Out in Arcellx Cell Therapy's ASH Data, But Don't Overlook Manufacturing Advantages | ||
| ADMA BIOLOGICS | 19,210 | 0,00 % | ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip? | ||
| ANNEXON | 4,870 | 0,00 % | Annexon Biosciences: Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting | ||
| EVOTEC | 8,955 | +1,65 % | INDEX-MONITOR: JPMorgan erwartet Evotec zurück im MDax - Dax unverändert | NEW YORK (dpa-AFX) - Zur Index-Überprüfung der Deutschen Börse an diesem Mittwochabend erwartet die US-Bank JPMorgan Kontinuität im Leitindex Dax . Im MDax DE0008467416>, dem Index für mittelgroße... ► Artikel lesen | |
| QUANTUM-SI | 2,255 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| METAGENOMI | 4,160 | 0,00 % | Metagenomi, Inc.: Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting | ||
| BIONTECH | 112,50 | +1,17 % | BioNTech, Medigene und Bayer: Deutsche Biotech-Unternehmen revolutionieren die Krebstherapie | In der Onkologie stehen spannende neue Entwicklungen an: BioNTech wandelt sich vom Covid-19-Impfstoffhersteller zum Krebsmedikamenten-Spezialisten. Mit der Übernahme des chinesischen Unternehmens Biotheus... ► Artikel lesen |
BIOSERGEN AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,07 % bei einem Aktienkurs von 0,052 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.
